Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 6, Issue 5, 2012, Pages

  Sharma, Meenakshi ^a   Sehgal, Rakesh ^b   Kaur, Sukhbir ^a  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; CALCIUM; CHLORIDE; CISPLATIN; CREATININE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LACTATE DEHYDROGENASE; MAGNESIUM; PHOSPHATE; SILIBININ; SODIUM; STIBOGLUCONATE SODIUM; UREA; URIC ACID; ANTIPROTOZOAL AGENT; CYTOKINE; IMMUNOLOGIC FACTOR; PROTECTIVE AGENT; PROTOZOON ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL DISEASE; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; IMMUNOMODULATION; KIDNEY FUNCTION TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LEISHMANIA DONOVANI; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LIVER TOXICITY; MORTALITY; MOUSE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PARASITE LOAD; RENAL PROTECTION; SIDE EFFECT; TH1 CELL; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; DRUG EFFECT; HUMAN; KIDNEY; PHYSIOLOGY; SECRETION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIOXIDANTS; ANTIPROTOZOAL AGENTS; CISPLATIN; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; PARASITE LOAD; PROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 84863669129     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001629     Document Type: Article

References (83)

1. Herwaldt BL, (1999) Leishmaniasis. Lancet 354 (9185): 1191-1199.
2. Sundar S, Chatterjee M, (2006) Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 123 (3): 345-352.
3. Murray HW, (2001) Clinical and experimental advances in the treatment of visceral leishmaniasis. Antimicrob Agents Chemother 45 (8): 2185-2197.
4. Kshirsagar NA, Bodhe P, Kotwani RN, (1997) Targeted drug delivery in visceral leishmaniasis. J Parasit Dis 21: 21-24.
5. Thakur CP, Bhowmick S, Dolfi L, Olliaro P, (1995) Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 89 (2): 219-223.
6. Fuertes MA, Castilla J, Alonso C, Perez JM, (2002) Novel concepts in the development of platinum antitumor drugs. Curr Med Chem Anti-Cancer Agents 2: 539-551.
7. Merritt RE, Mahtabifard A, Yamada RE, Crystal RG, Korst RJ, (2003) Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc Surg 126 (5): 1609-1617.
8. Collins JL, Kao M, (1989) The anticancer drug, cisplatin increases the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother 29 (1): 17-22.
9. Tavares J, Quaissi M, Quaissi A, Cordeiro-da-Silva A, (2007) Characterization of anti-Leishmania effect induced by cisplatin, an anticancer drug. Acta Tropica 103 (2): 133-141.
10. Kaur S, Sachdeva H, Dhuria S, Sharma M, Kaur T, (2010) Antileishmanial effect of cisplatin against murine visceral leishmaniasis. Parasitol Int 59 (1): 62-69.
11. Pinzani V, Bressolle F, Hauq IJ, Galtier M, Blayac JP, Balmes P, (1994) Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35 (1): 1-9.
12. Kawai Y, Kohda Y, Kodawara T, Gemba M, (2005) Protective effect of a protein kinase inhibitor on cellular injury induced by cephaloridine in the porcine kidney cell line LLC-PK (1). J Toxicol Sci 30 (3): 157-163.
13. Taguchi T, Na zneen A, Abid MR, Razzaque MS, (2005) Cisplatin-associated nephrotoxicity and pathological events. Review Contrib Nephrol 148: 107-121.
14. Meyer BR, Lewin M, Drayer DE, Pasmantier M, Lonski L, (1984) Optimizing metoclopramide control of cisplatin-induced emesis. Ann Intern Med 100 (3): 393-395.
15. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, et al. (1996) Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant 11 (1): 55-62.
16. Appenroth D, Froeb S, Kersten L, Splinter FK, Winnefeld K, (1997) Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol 71 (11): 677-683.
17. Kaur S, Kaur T, Garg N, Mukherjee S, Raina P, et al. (2008) Effect of dose and route of inoculation on the generation of CD4+ Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 103 (6): 1413-1419.
18. Narayana K, Verghese S, Jacob SS, (2009) L-Ascorbic acid partially protects two cycles of cisplatin chemotherapy-induced testis damage and oligo-astheno-teratospermia in a mouse model. Exp Toxicol Pathol 61 (6): 553-563.
19. Bradley DJ, Kirkley J, (1977) Regulation of Leishmania population within host. I. The variable of Leishmania donovani infections in mice. Clin Exp Immunol 30 (1): 119-129.
20. Nagill R, Mahajan R, Sharma M, Kaur S, (2009) Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol Int 58 (4): 359-366.
21. Khynriam D, Prasad SB, (2001) Hematotoxicity and blood glutathione levels after cisplatin treatment of tumor-bearing mice. Cell Biol Toxicol 17 (960): 357-370.
22. Trotter ER, Peters W, Robinson BL, (1980) The experimental chemotherapy of leishmaniasis IV. The development of rodent model for visceral infection. Ann Trop Med Parasitol 74 (2): 127-138.
23. Thakur CP, Kumar M, Pandey AK, (1991) Comparison of regimens of treatment of antimony resistant kala-azar patients: A randomized study. Am J Trop Hyg 45 (4): 435-441.
24. Karki P, Koirala S, Parija SC, Hansdak SG, Das ML, (1998) A thirty day course of sodium stibogluconate for the treatment of kala-azar in Nepal. Southeast Asian J Trop Med Public Health 29 (1): 154-158.
25. Rahim F, Rehman F, Ahmad S, Zada B, (1998) Visceral leishmaniasis in District Dir, NWFP. J Pak Med Assoc 48 (6): 161-162.
26. Khalil EA, el Hassan AM, Zijlstra EE, Hashim FA, Ibrahim ME, et al. (1998) Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: Management of those who do not respond. Ann Trop Med Parasitol 92 (2): 131-138.
27. Geib G, Pozzi B, Lazaretti NS, Dutra C, Pereira M, et al. (2009) Mortality rate with irinotecan/cisplatin plus concomitant radiation therapy in patients with locally advanced esophageal squamous cell carcinoma. J Clin Oncol 27.
28. Ripoll E, Rama BN, Webber MM, (1986) Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. J Urol 136: 529-531.
29. Ciaccio MTL, Pintaudi AM, (1994) Vitamin A preserves the cytotoxic activity of adriamycin while counteracting its peroxidative effects in human leukemic cells in vitro. Biochem Mol Biol Int 34: 329-335.
30. Shimpo KNT, Yamada K, (1991) Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 54: 1298-1301.
31. Jotti AMM, Paracchini L, Piccinini F, Ursini F, (1994) Protective effect of dietary selenium supplementation on delayed cardiotoxicity of adriamycin in rat: is PHGPX but not GPX involved? Free Radic Biol Med 16: 284-288.
32. De Rossel RA, Bray RS, Alexander J, (1987) The correlation between delayed-type hypersensitivity, lymphocyte activation and protective immunity in experimental murine leishmaniosis. Parasite Immunol 9 (1): 105-115.
33. Reiner SL, Locksley RM, (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13: 151-177.
34. Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL, (1989) Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol 143 (12): 4244-4249.
35. Tripathi P, Singh V, Naik S, (2007) Immuneresponse to leishmania:paradox rather than paradigm. FEMS Immunol Med Microbiol 51 (2): 229-242.
36. Huang X, Chen YT, Song HZ, Huang GC, Chen LB, (2011) Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol 17 (25): 3002-3011.
37. Park HR, Ju EJ, Jo SK, Jung U, Kim SH, (2009) Enhanced antitumor efficacy of cisplatin in combination with HemoHim in tumor-bearing mice. BMC Cancer 9: 85.
38. Trinchieri G, (2001) Regulatory role of T cells producing both interferon-γ and interleukin-10 in persistent infection. J Exp Med 194 (10): 53-57.
39. Lehmann J, Ensslt KH, Lehmann I, Emmendorfer A, Lohmann-Mattes ML, (2000) The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility of Leishmania donovani infecteion in mice. J Interferon Cytokine Res 20 (1): 63-67.
40. D'Oliveira A, Costa SR, Barbosa AB, Orge M de la G, Carvalho EM, (1997) Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis. Mem Inst Oswaldo Cruz 92 (1): 15-20.
41. Kemp M, Kemp J, Kahrazmi A, Ismail A, Kurtzhals JA, et al. (1999) Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 116 (3): 500-504.
42. Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L, (2000) A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 18 (3): 281-289.
43. Hartmann JT, Lipp HP, (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4 (6): 889-901.
44. Sastry JK, Kellie SJ, (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22 (5): 441-445.
45. Arany I, Safirstein R, (2003) Cisplatin nephrotoxicity. Semin Nephrol 23 (5): 460-464.
46. Sugihara K, Gemba M, (1986) Modification of cisplatin toxicity by antioxidants. Jpn J Pharmacol 40 (2): 353-355.
47. Saeed AM, Khalil EA, Elhassan AM, Hashim FA, Elhassan AM, et al. (1998) Serum erythropoietin concentration in anaemia of visceral leishmaniasis (kala-azar) before and during antimonial therapy. Br J haematol 100 (4): 720-724.
48. Nair SC, Salomi M, Panikkar B, Panikkar KR, (1991) Modulatory effects of Crocus sativus and Nigella sativa extracts on cisplatin induced toxicity in mice. J Ethnopharmacol 31 (1): 75-83.
49. Kallan BM, Singh K, Aggarwal NP, Singh M, (1982) Lliver enzymes during treatment with reserve regimen. Ind J of Tub 29 (4): 226-231.
50. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, (2007) Injectable paromomycin for visceral leishmaniasis in India. Eng J Med 356 (25): 2571-2581.
51. Costaa JD, de Nazareth Meirelles M, Eduardo Pereira Vellosob C, Porrozzia R, (2007) Leishmania chagasi: Cytotoxic effect of infected macrophages on parenchymal liver cells. 117 (4): 390-398.
52. Zicca A, Cafaqqi S, Mariggio MA, Vannozzi MO, Ottone M, Bocchini V, Caviglioli G, Viale M, (2002) Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats. Eur J Pharmacol 442 (3): 265-272.
53. Liu J, Liu Y, Habeebu SS, Klaassen CD, (1998) Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol Appl Pharmacol 149 (1): 24-31.
54. Kikkawa R, Yamamoto T, Fukushima T, Yamada H, Horii I, (2005) Investigation of a hepatotoxicity screening system in primary cell cultures-"What biomarkers would need to be addressed to estimate toxicity in conventional and new approaches?". J Toxicol Sci 30 (1): 61-72.
55. Schreiber S, Hamling J, Zehnter E, Howaldt S, Daerr W, et al. (1997) Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 40 (6): 761-766.
56. Sudhakar D, Krishna Kishore R, Parthasarathy PR, (2010) Portulaca oleracea L. extract ameliorates the cisplatin-induced toxicity in chick embryonic liver. Indian J Biochem Biophys 47 (3): 185-189.
57. Christova TY, Gorneva GA, Taxirov SI, Duridanova DB, Setchenska MS, (2003) Effect of cisplatin and cobalt chloride on antioxidant enzymes in the livers of Lewis lung carcinoma-bearing mice: Protective role of heme oxygenase. Toxicol Lett 138 (3): 235-242.
58. Molander DW, Sheppard E, Payne MA, (1957) Serum transaminase in liver disease. J Am Med Assoc 163 (16): 1461-1465.
59. Lorenz D, Lucker PW, Mennicke WH, Wetzelsberger N, (1984) Pharmacokinetic studies with silymarin in human serum and bile. Methods Find. Exp Clin Pharmacol 6 (10): 655-661.
60. Muriel P, Mourelle M, (1990) Prevention by silymarin of membrane alterations in acute CCL4 liver damage. J Appl Toxicol 10 (4): 275-279.
61. Seo MY, Lee SM, (2002) Protective effect of low dose of ascorbic acid on hepatobiliary function in hepatic ischemia/reperfusion in rats. J Hepatol 36: 72-77.
62. Crofton J, Andrews D, (1977) Respiratory diseases Backwell Scientific Publications. Medical Book Centre.
63. Daugarrd G, Abildqaard U, Holtei-Rathlou NH, Brunshuns I, Bucher D, (1988) Renal tubular function in patients treated with high dose cisplatin. Clin Pharmacol Ther 44 (2): 164-172.
64. Badary OA, Naqi M, Al-Sawaf HA, Al-Harbi M, Al-Bekairi AM, (1997) Effect of L-histidinol on cisplatin nephrotoxicity in the rats. Nephron 77 (4): 435-439.
65. Bogin E, Marom M, Levi Y, (1994) Changes in serum, liver and kidneys of cisplatin-treated rats; effects of antioxidants. Eur J Clin Chem Clin Biochem 32 (11): 843-851.
66. Sheena N, Ajith TA, Janardhanan KK, (2003) Prevention of nephrotoxicity induced by the anticancer drug cisplatin, using Ganoderma lucidum, a medicinal mushroom occurring in South India. Curr Sci 85 (4): 478-482.
67. el Weshi A, Thieblemont C, Cottin V, Barbet N, Catimel G, (1995) Cisplatin- induced hyponatremia and renal sodium wasting. Acta Oncol 34 (2): 264-265.
68. Carney SL, Wonq NL, Quamme GA, Dirks JH, (1980) Effect of magnesium deficiency on renal magnesium and calcium transport in the rat. J Clin Invest 65 (1): 180-188.
69. Ariceta G, Rodriquez-Soriano J, Vallo A, Navajas A, (1997) Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28 (1): 35-40.
70. Buckley JE, Clark VL, Meyer TJ, Pearlman NW, (1984) Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 144 (12): 2347-2348.
71. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, et al. (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 (9): 673-680.
72. Ries F, Klastersky J, (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8 (5): 368-379.
73. Goren MP, (2003) Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Med Pediatr Oncol 41 (3): 186-189.
74. Hoffmann K, Marten A, Lindel K, Fritz S, Jager D, et al. (2006) Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5- fluorouracil and interpheron alpha: report on several cases and review of the literature. BMC Cancer 6: 128.
75. Ajith TA, Jose N, Janardhanan KK, (2002) Amelioration of cisplatin induced nephrotoxicity in mice by ethyl acetate extract of a polypore fungus, Phellinus rimosus. J Exp Clin Cancer Res 21 (2): 487-491.
76. Cetin R, Devrim E, Kilicoglu B, Avei A, Candir O, Durak I, (2006) Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol 26 (1): 42-46.
77. Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, et al. (2004) Supplementation with antioxidant micronutrients and chemotherapy- induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomized, double-blind, placebo-controlled study. Eur J Cancer 40 (11): 1713-1723.
78. Kedziora-Kornatowska K, Szram S, Kornatowski T, Szadujkis-Szadurski L, Kedziora J, et al. (2003) Effect of vitamin E and vitamin C supplementation on antioxidative state and renal glomerular basement membrane thickness in diabetic kidney. Nephron Exp Nephrol 95 (4): 134-143.
79. Patra RC, Swarup D, Dwivedi SK, (2001) Antioxidant effect of α-tocopherol, ascorbic acid and L-methionine on lead induced oxidative stress to the liver, kidney and brain in rats. Toxicol 162 (2): 81-88.
80. Ajith TA, Usha S, Nivitha V, (2007) Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 375: 82-86.
81. Valenzuela A, Lagos C, Schmidt K, Videla L, (1985) Sylimarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in rats. Biochem Pharmacol 34 (12): 2209-2212.
82. Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, et al. (1985) Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 28 (6): 914-921.
83. Alarcan de la Lastra Martin MJ, Motilva V, (1991) Effects of naringenin and silymarin on urinary excretion of water and electrolytes in rats. Phytother Res 5: 191-193.